Real-world data/evidence case studies

This case study highlights the strategic execution of an Expanded Access Program (EAP) across multiple global regions, Europe, Asia-Pacific, and Latin America, following a Phase 3 clinical study.

During the peak of the COVID-19 pandemic, a global compassionate use program (CUP) was urgently needed to provide compassionate use of a promising treatment. The program required rapid deployment across multiple regions to support hospitalized patients.

To ensure continuity of care for participants in the maintenance phase of multiple parent studies in oncology managed by ICON and third-party vendors, a consolidated long-term extension (LTE) protocol was required.

An oncology study involving 53 parent protocols - each with distinct timelines, sites, databases, and reporting requirements - needed to be integrated into a single open-label extension (OLE) study.

An established customer sought to streamline patient follow-up across multiple clinical protocols, each involving different sponsors and assets, to support ongoing treatment and safety data collection.

A major Point of Care (PoC) Publisher partnered with Symphony Health to evaluate an unbranded cardiovascular treatment campaign targeting hospital-affiliated physicians nationwide. The campaign used printed condition guides to engage HCPs and patients during key decision-making moments.

Symphony Health partnered with a social media company to develop a privacy-compliant ad measurement solution for a pharma client. Using machine learning, they maintained 90% accuracy while meeting stricter privacy standards—offering a scalable model for regulated environments.

Understanding Social Determinants of Health (SDOH) is key to addressing disparities and improving outcomes in Type 2 Diabetes. While factors like diet and access to care are known, quantifying their impact on diagnosis, treatment initiation, and adherence remains an emerging focus.

A pharma company partnered with Symphony Health to guide the launch of a TYK2 inhibitor for psoriasis. They explored market potential, free drug programs, treatment patterns, and prescribing behavior—especially among NPs and PAs—to shape positioning in a competitive landscape.

CGRP inhibitors have expanded migraine treatment, but payer barriers often limit access, especially for vulnerable groups. A patient advocacy client worked with Symphony Health to explore disparities in access and their impact on outcomes like ER visits and hospitalizations.

Early cancer detection is vital, yet many cases—especially lung cancer—are diagnosed late, limiting treatment options. Life sciences organizations now use real-world data and machine learning to identify subtle, pre-diagnostic signals in patient journeys, enabling earlier intervention and improved outcomes.

Pulmonary arterial hypertension (PAH) often presents with vague symptoms, making diagnosis difficult and leading to frequent delays or misdiagnoses. While current treatments have improved outcomes, underserved populations with limited access to specialized care remain under treated.